The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Alpha-Antitrypsin Deficiency Treatment-Global Market Insights and Sales Trends 2025
Synopsis
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global Alpha- Antitrypsin Deficiency Treatment market size is expected to reach US$ 3443.4 million by 2029, growing at a CAGR of 9.0% from 2023 to 2029. The market is mainly driven by the significant applications of Alpha- Antitrypsin Deficiency Treatment in various end use industries. The expanding demands from the Clinic, Hospital and Others,, are propelling Alpha- Antitrypsin Deficiency Treatment market. CT-2009, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the POL-6014 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alpha- Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alpha- Antitrypsin Deficiency Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alpha- Antitrypsin Deficiency Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alpha- Antitrypsin Deficiency Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alpha- Antitrypsin Deficiency Treatment covered in this report include Adverum Biotechnologies, Inc., Alnylam Pharmaceuticals, Inc., Applied Genetic Technologies Corporation, Arrowhead Pharmaceuticals, Inc., Carolus Therapeutics, Inc., Cevec Pharmaceuticals GmbH, Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L. and Editas Medicine, Inc., etc.
The global Alpha- Antitrypsin Deficiency Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Global Alpha- Antitrypsin Deficiency Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alpha- Antitrypsin Deficiency Treatment market, Segment by Type:
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Global Alpha- Antitrypsin Deficiency Treatment market, by Application
Clinic
Hospital
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Alpha- Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global Alpha- Antitrypsin Deficiency Treatment market size is expected to reach US$ 3443.4 million by 2029, growing at a CAGR of 9.0% from 2023 to 2029. The market is mainly driven by the significant applications of Alpha- Antitrypsin Deficiency Treatment in various end use industries. The expanding demands from the Clinic, Hospital and Others,, are propelling Alpha- Antitrypsin Deficiency Treatment market. CT-2009, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the POL-6014 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alpha- Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alpha- Antitrypsin Deficiency Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alpha- Antitrypsin Deficiency Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alpha- Antitrypsin Deficiency Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alpha- Antitrypsin Deficiency Treatment covered in this report include Adverum Biotechnologies, Inc., Alnylam Pharmaceuticals, Inc., Applied Genetic Technologies Corporation, Arrowhead Pharmaceuticals, Inc., Carolus Therapeutics, Inc., Cevec Pharmaceuticals GmbH, Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L. and Editas Medicine, Inc., etc.
The global Alpha- Antitrypsin Deficiency Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Global Alpha- Antitrypsin Deficiency Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alpha- Antitrypsin Deficiency Treatment market, Segment by Type:
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Global Alpha- Antitrypsin Deficiency Treatment market, by Application
Clinic
Hospital
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Alpha- Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Alpha- Antitrypsin Deficiency Treatment
1.1 Alpha- Antitrypsin Deficiency Treatment Market Overview
1.1.1 Alpha- Antitrypsin Deficiency Treatment Product Scope
1.1.2 Alpha- Antitrypsin Deficiency Treatment Market Status and Outlook
1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2018-2029)
1.4 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Region (2018-2023)
1.5 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Alpha- Antitrypsin Deficiency Treatment Market Size (2018-2029)
1.6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2018-2029)
1.6.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size (2018-2029)
1.6.4 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size (2018-2029)
2 Alpha- Antitrypsin Deficiency Treatment Market by Type
2.1 Introduction
2.1.1 CT-2009
2.1.2 POL-6014
2.1.3 ARO-AAT
2.1.4 ALNAAT-02
2.1.5 Others
2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Type (2018-2029)
3 Alpha- Antitrypsin Deficiency Treatment Market Overview by Application
3.1 Introduction
3.1.1 Clinic
3.1.2 Hospital
3.1.3 Others
3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Revenue Breakdown by Application (2018-2029)
4 Alpha- Antitrypsin Deficiency Treatment Competition Analysis by Players
4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2022)
4.3 Date of Key Players Enter into Alpha- Antitrypsin Deficiency Treatment Market
4.4 Global Top Players Alpha- Antitrypsin Deficiency Treatment Headquarters and Area Served
4.5 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Adverum Biotechnologies, Inc.
5.1.1 Adverum Biotechnologies, Inc. Profile
5.1.2 Adverum Biotechnologies, Inc. Main Business
5.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.1.4 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Adverum Biotechnologies, Inc. Recent Developments
5.2 Alnylam Pharmaceuticals, Inc.
5.2.1 Alnylam Pharmaceuticals, Inc. Profile
5.2.2 Alnylam Pharmaceuticals, Inc. Main Business
5.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.2.4 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Alnylam Pharmaceuticals, Inc. Recent Developments
5.3 Applied Genetic Technologies Corporation
5.3.1 Applied Genetic Technologies Corporation Profile
5.3.2 Applied Genetic Technologies Corporation Main Business
5.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
5.4 Arrowhead Pharmaceuticals, Inc.
5.4.1 Arrowhead Pharmaceuticals, Inc. Profile
5.4.2 Arrowhead Pharmaceuticals, Inc. Main Business
5.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.4.4 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
5.5 Carolus Therapeutics, Inc.
5.5.1 Carolus Therapeutics, Inc. Profile
5.5.2 Carolus Therapeutics, Inc. Main Business
5.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.5.4 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Carolus Therapeutics, Inc. Recent Developments
5.6 Cevec Pharmaceuticals GmbH
5.6.1 Cevec Pharmaceuticals GmbH Profile
5.6.2 Cevec Pharmaceuticals GmbH Main Business
5.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Cevec Pharmaceuticals GmbH Recent Developments
5.7 Dicerna Pharmaceuticals, Inc.
5.7.1 Dicerna Pharmaceuticals, Inc. Profile
5.7.2 Dicerna Pharmaceuticals, Inc. Main Business
5.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.7.4 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Dicerna Pharmaceuticals, Inc. Recent Developments
5.8 Digna Biotech, S.L.
5.8.1 Digna Biotech, S.L. Profile
5.8.2 Digna Biotech, S.L. Main Business
5.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Digna Biotech, S.L. Recent Developments
5.9 Editas Medicine, Inc.
5.9.1 Editas Medicine, Inc. Profile
5.9.2 Editas Medicine, Inc. Main Business
5.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.9.4 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Editas Medicine, Inc. Recent Developments
5.10 Grifols, S.A.
5.10.1 Grifols, S.A. Profile
5.10.2 Grifols, S.A. Main Business
5.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Grifols, S.A. Recent Developments
5.11 Inhibrx
5.11.1 Inhibrx Profile
5.11.2 Inhibrx Main Business
5.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.11.4 Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Inhibrx Recent Developments
5.12 Intellia Therapeutics, Inc.
5.12.1 Intellia Therapeutics, Inc. Profile
5.12.2 Intellia Therapeutics, Inc. Main Business
5.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.12.4 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Intellia Therapeutics, Inc. Recent Developments
5.13 International Stem Cell Corporation
5.13.1 International Stem Cell Corporation Profile
5.13.2 International Stem Cell Corporation Main Business
5.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.13.4 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 International Stem Cell Corporation Recent Developments
5.14 Ionis Pharmaceuticals, Inc.
5.14.1 Ionis Pharmaceuticals, Inc. Profile
5.14.2 Ionis Pharmaceuticals, Inc. Main Business
5.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.14.4 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Ionis Pharmaceuticals, Inc. Recent Developments
5.15 Kamada Ltd.
5.15.1 Kamada Ltd. Profile
5.15.2 Kamada Ltd. Main Business
5.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.15.4 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 Kamada Ltd. Recent Developments
5.16 Polyphor Ltd.
5.16.1 Polyphor Ltd. Profile
5.16.2 Polyphor Ltd. Main Business
5.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.16.4 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.16.5 Polyphor Ltd. Recent Developments
5.17 ProMetic Life Sciences Inc.
5.17.1 ProMetic Life Sciences Inc. Profile
5.17.2 ProMetic Life Sciences Inc. Main Business
5.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.17.4 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.17.5 ProMetic Life Sciences Inc. Recent Developments
5.18 rEVO Biologics, Inc.
5.18.1 rEVO Biologics, Inc. Profile
5.18.2 rEVO Biologics, Inc. Main Business
5.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.18.4 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.18.5 rEVO Biologics, Inc. Recent Developments
5.19 Sangamo BioSciences, Inc.
5.19.1 Sangamo BioSciences, Inc. Profile
5.19.2 Sangamo BioSciences, Inc. Main Business
5.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
5.19.4 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.19.5 Sangamo BioSciences, Inc. Recent Developments
6 North America
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Alpha- Antitrypsin Deficiency Treatment Market Dynamics
11.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
11.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers
11.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
11.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
